Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Combined treatment with omalizumab and etanercept in a patient with chronic spontaneous urticaria and rheumatoid arthritis

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Drug survival of guselkumab for psoriasis in a real-world setting: a single-center retrospective chart review

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Systematic review of machine learning for diagnosis and prognosis in dermatology

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Caring for young people with moderate to severe psoriasis: an interpretive description of parental perspectives

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Drug survival of secukinumab for psoriasis in a real-world setting

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Management of Ocular Manifestations of Atopic Dermatitis: A Consensus Meeting Using a Modified Delphi Process

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Atopic dermatitis is associated with increased use of social benefits: a register-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Clinical Management of Atopic Dermatitis in Adults: Mapping of Expert Opinion in 4 Nordic Countries using a Modified Delphi Process

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The prevalence of atopic dermatitis in adults: systematic review on population studies

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

We present a case report of a 64-year old female patient with rheumatoid arthritis and chronic spontaneous urticaria. She was treated with a combination of etanercept and omalizumab with good results and no adverse effects. In selected patients with severe inflammatory disease activity it is worth considering combined biologic therapy. However, treatment should be closely monitored as short-term and long-term side effects are not properly elucidated.

Original languageEnglish
JournalThe Journal of dermatological treatment
Volume30
Issue number4
Pages (from-to)387-388
Number of pages2
ISSN0954-6634
DOIs
Publication statusPublished - Jun 2019

    Research areas

  • Adult, Anti-Allergic Agents/therapeutic use, Antirheumatic Agents/therapeutic use, Arthritis, Rheumatoid/drug therapy, Chronic Disease, Drug Therapy, Combination, Etanercept/therapeutic use, Female, Humans, Omalizumab/therapeutic use, Urticaria/drug therapy

ID: 59165943